Pegasys and Hepatitis C

This is double blinded study to compare the efficacy and safety of 360 μg induction dosing of Pegasys for 12 weeks and then followed by a 180 μg maintenance dose of Pegasys for an additional 36 weeks with the combination of Copegus for 48 weeks. The fixed dosing of Pegasys in combination with Copegus for 48 weeks are for patients with genotype 1 and chronic hepatitis C infection of high viral titer and baseline body weight equal to or greater than 85kg (approximately 187 pounds).

You may be eligible for this study if you have:

• Body weight ≥ 85kg  (approximately 187 pounds).
• Genotype 1
• Serum HCV RNA quantifiable  at ≥ 400,000 IU/ml
• Serological evidence of chronic hepatitis C infection by an anti-HCV antibody test.

For more information, please contact the number